About nLife

• nLife Therapeutics is a biopharmaceutical company leading the discovery and development of cell specific oligonucleotides as therapeutic agents for Central Nervous System and Neuromuscular disorders


• nLife Therapeutics was established in 2010 and the investors are private Angels and 3 Spanish VC´s (Crossroad Biotech,  Caixa Capital Biomed and HealthEquity). nLife has assembled a world class scientific and management team to support the development of its nucleic acid delivery platform


• nLife Therapeutics  has found a way to deliver oligonucleotides to neurons and selected cell populations by means of active receptor mediated up-take. Now it is evolving the “gene silencing platform” to “non viral gene therapy” by means of CRISPR/CAS9 RNP delivery.

 Early Recognition

• In 2012 Pfizer Foundation (Spain) awarded the Best Basic Research Prize to nLife based on the publication: Molecular Psychiatry. doi:10.1038/mp.2011.92: Bortolozzi, A., Castañé, A., Semakova, J., Santana, N., Alvarado, G., Cortés, R., et al. (2011). Selective siRNA-mediated suppression of 5-HT(1A) autoreceptors evokes strong anti-depressant-like effects.


• In 2014 the Michael Jay Fox Foundation awarded nLife with a grant to support the characterization of the compound NLF-PD-1233 against alpha-synuclein as novel disease modifying treatment for Parkinson’s disease.